Is it possible to stop taking brigatinib/brigatinib (Embry) after taking it for a long time?

Brigatinib/Brigatinib (Brigatinib) is a targeted therapy for ALK-positive non-small cell lung cancer and is usually used for the long-term management of patients with locally advanced or metastatic disease. Its efficacy relies on sustained inhibition of the ALK signaling pathway, so long-term administration is the core strategy to maintain disease control. Whether the patient can stop taking the drug on his own after achieving curative effect requires comprehensive consideration of tumor biological characteristics, patient tolerance and drug safety.

Clinical experience and pharmacological studies have shown that sudden discontinuation of treatment may lead to reactivation of tumor cells and an increased risk of disease recurrence or progression. This is because brigatinib inhibits tumor signaling by irreversibly binding to ALK. If the drug is stopped and ALK signaling becomes active, tumor cells may proliferate rapidly. Therefore, it is generally not recommended that patients stop taking medications on their own, and should be done under the guidance of a professional oncologist even when symptoms are relieved or imaging shows stable disease.

For patients taking long-term medication, doctors will adjust the dose based on adverse reactions, blood indicators, and liver and kidney function monitoring to improve tolerance. If obvious toxicity or intolerable side effects occur, the dose can be appropriately reduced or the drug temporarily discontinued, and the drug can be gradually restored to a safe dose after the symptoms are relieved. In addition, when brigatinib is used in combination or when comorbidities occur, the risk of discontinuation must be carefully assessed to avoid affecting the long-term efficacy.

In short, brigatinib is a drug that targets long-term tumor control, and long-term use is an important part of maintaining the therapeutic effect. Any discontinuation or adjustment plan should be carried out under the guidance of a physician, combined with regular imaging monitoring and blood tests, to ensure that the patient achieves both efficacy and a reduced risk of side effects. Patients should also maintain good lifestyle and follow-up habits in daily management to provide support for long-term targeted therapy.

Reference materials:https://www.alunbrig.com/